Home Browse Update Summary

This process involves analyzing complex genetic data and may take a moment.

Return Search

PDX ID	369R
Host Strain(and Source)	NSG Source: Monash University
Host Strain Immune system Humanized	NO
Host Type	Testosterone supplemented
Graft Site	Subcutaneous
Current Generation (* indicates number of generations grown in Castrate host)	9
Average PDX Generation Time (days +/- SEM)	105 ± 9
Tumour preparation	Tumor solid
Tumour Characterization Technology	Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq
Tumour confirmed not to be of Mouse/EBV origin	Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC
Passage QA performed	Routine QA every 2-3 passages
Associated meta data
PDX model availability	Yes (fixed, frozen)
Governance restriction for distribution	Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements
Pubmed ID	34413304

This heatmap displays the call type of curated CNVs in the presented samples.

This heatmap displays the call type of CNVs in commonly occurred samples.

This table displays curated CNVs

PDX ID	Gene Symbol	CNV Log2	CNV Copy	CNV Call	Experiments name	Platform	Reference genome
369R	KMT2A	0.705	3.261	Gain	MURAL Prostate Cancer PDX collection	Targeted GARVAN Panel	hg19
369R	PTEN	-9.834	0.002	Homdel	MURAL Prostate Cancer PDX collection	Targeted GARVAN Panel	hg19
369R	PTEN	-1.819	0.567	Loss	MURAL Prostate Cancer PDX collection	Targeted GARVAN Panel	hg19
369R	SUFU	-1.819	0.567	Loss	MURAL Prostate Cancer PDX collection	Targeted GARVAN Panel	hg19
369R	CDKN1B	-0.750	1.189	Loss	MURAL Prostate Cancer PDX collection	Targeted GARVAN Panel	hg19
369R	BRCA2	-0.921	1.056	Loss	MURAL Prostate Cancer PDX collection	Targeted GARVAN Panel	hg19
369R	RB1	-0.738	1.199	Loss	MURAL Prostate Cancer PDX collection	Targeted GARVAN Panel	hg19
369R	AKT1	-0.930	1.049	Loss	MURAL Prostate Cancer PDX collection	Targeted GARVAN Panel	hg19
369R	ZFHX3	-1.061	0.959	Loss	MURAL Prostate Cancer PDX collection	Targeted GARVAN Panel	hg19
369R	TP53	-0.797	1.151	Loss	MURAL Prostate Cancer PDX collection	Targeted GARVAN Panel	hg19

Sample Number	369R
Sample Site	Prostate
Sample source	Radical prostatectomy
Pathology Tumour Diagnosis	Adenocarcinoma
Gleason Score	9
Primary Gleason Score	4
Secondary Gleason Score	5
Tertiary Gleason Score	None
ISUP Grade Group	5
Tumour Grade	pT3bN0
D'Amico Risk Classification	7
Tumour Volume (in cc)	13.1
Treatment Prior to Specimen Collection	None

Patient Number	369
Sex	Male
Diagnosis	Prostate Cancer
PSA at diagnosis (ng/mL)	5.8
Consent to share data	Yes, subject to ethical review

Patient Tumour Collection (Current Model)
Tumour sample ID	369R
Patient Age (binned in 5 year age groups)	60-64

This heatmap displays the mutations of curated sequence variants.

This table displays curated sequence variants

PDX ID	Gene Symbol	Total Read Depth	Alternate Frequency	Consequence	Exon	GnomAD AF	CADD PHRED score	ClinVar significance	Platform	Experiments Name	Reference	Library Type	Instrument Type
369R	TP53	168	0.99	Missense variant	'7/11	0	29	Pathogenic	Targeted GARVAN Panel	MURAL Prostate Cancer PDX collection	hg19	paired	Illumina HiSeq 2500
369R	POMC	188	0.64	Missense variant	'3/3	0.000852	25.2	-	Targeted GARVAN Panel	MURAL Prostate Cancer PDX collection	hg19	paired	Illumina HiSeq 2500
369R	LRP2	395	0.52	Missense variant	'52/79	2.84E-05	22.2	-	Targeted GARVAN Panel	MURAL Prostate Cancer PDX collection	hg19	paired	Illumina HiSeq 2500
369R	LRP1B	412	0.46	Missense variant	'69/91	.	23.5	-	Targeted GARVAN Panel	MURAL Prostate Cancer PDX collection	hg19	paired	Illumina HiSeq 2500

No information in Drug dosing Table